Testing the safety of BNT351 in people with and without HIV
Part of Infections clinical trials.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- If you do not have HIV, you must be HIV-negative and willing to avoid high-risk behaviors.
- If you have HIV, you must have a CD4 count of at least 500 and a viral load between 5,000 and 100,000 copies/mL.
- You cannot have received an HIV vaccine or a similar antibody in another study.
- You cannot have certain immune system problems or be on certain medications.
- If you have HIV, you cannot have certain infections or AIDS-defining illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
This trial tests a new medicine, GS-0415, for people with HIV who are already on a stable treatment plan. It aims to see how safe and effective the new medicine is.
This trial tests whether giving a special neutralizing antibody (bNAb) early to infants living with HIV can help their immune system fight the virus better. It's for babies under 1 year old who are starting HIV treatment for the first time.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.